CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or <i>TP53</i> MutationsJeff P. Sharman, Franck Morschhauser, Yanwen Jiang et al.|Blood|2024Cited by 3
Different Clinical Implications of Kinase Domain BCR-ABL1 Variants Detected in Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia PatientsRicardo Sánchez, Joaquín Martínez‐López, Rosa Ayala et al.|Blood|2019Cited by 1
Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero TrialLucía Pérez‐Lamas, Valentín García‐Gutiérrez, Juan Carlos Hernández‐Boluda et al.|Blood|2023Cited by 1
Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trialJ. Sharman, Franck Morschhauser, Luca Laurenti et al.|Blood|2026Cited by 1
Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax-Obinutuzumab in the Randomized Phase 3 CRISTALLO TrialPaolo Sportoletti, Jeff P. Sharman, Luca Laurenti et al.|Blood|2024Cited by 0